In February 2017, the acquisition of Nasdaq listed SIgnal Genetics was completed with the merged entity becoming known as miRagen Therapeutics trading on Nasdaq with the symbol MGEN. miRagen Pharmaceuticals is a biopharmaceutical company developing innovative microRNA (miRNA) based therapeutics for the treatment of cardiovascular and muscle disease. miRNAs are a recently discovered class of small RNAs encoded in the genome. They are short, single-stranded RNA molecules that regulate gene expression with the potential to play a vital role in influencing the pathways responsible for cardiovascular and muscle disorders. miRagen is leveraging its core capabilities in miRNA profiling, oligonucleotide medicinal chemistry, cellular analysis, and in vivo testing in disease models to select highly potent modulators that target lead miRNAs in disease-specific pathways.
